CXCR4 and cancer: Since U87-CXCR4 cells are of human origin and the CCMCNPs were injected into immunocompetent mice, our study did not demonstrate a cancer-cell specific immune response, but identified the possibility of using such formulations together with immunogenic adjuvants in combination with checkpoint inhibitors for cancer treatment.